Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Denosumab in Giant Cell Tumor of Bone
NCT03301857Phase 4Completed
- Sponsor
- Amgen
- Start
- Nov 2017
- Primary completion
- Jul 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 4 trial of denosumab in Giant Cell Tumor of Bone (GCTB), sponsored by Amgen. Started Nov 2017; status: completed.
02
Drugs
denosumab
03
Conditions
Giant Cell Tumor of Bone (GCTB)
Beyond the preview
Go deeper on NCT03301857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03301857.